Quantcast

Latest HUMIRA Stories

2009-09-08 09:11:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Prescription Drugs http://www.reportlinker.com/p0131233/Prescription-Drugs.html This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class - Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists,...

2009-09-08 08:59:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. FoodService Disposables http://www.reportlinker.com/p0131234/FoodService-Disposables.html This report analyzes the US market for FoodService Disposables in Millions of US$ by the following Product Types: Cups and Lids, Containers, Dinnerware, Napkins, and Others. This report also analyzes the US Market for Foodservice Disposables by End-Use Segments: Restaurants,...

2009-07-15 06:48:00

ABBOTT PARK, Ill., July 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2009. Diluted earnings per share, excluding specified items, were $0.89, at the high end of Abbott's second-quarter guidance range of $0.87 to $0.89. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.83. Worldwide operational sales, which excludes an unfavorable 8.0 percent effect of exchange rates,...

2009-06-30 14:16:54

The U.S. District Court in Marshall, Texas, ordered Abbott Laboratories to pay Johnson & Johnson $1.7 billion in patent-related damages. Attorneys for Johnson & Johnson said Abbott's rheumatoid arthritis drug Humira, one of the top-selling drugs in the world, was made using technology developed exclusively for Johnson & Johnson at New York University. Humira earned more than $4 billion in sales in 2008. It differs from Johnson & Johnson's product Remicade, as it is fully...

2009-04-30 10:49:00

Newly Approved Simponi is Expected to Achieve Strong Uptake in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., April 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA)...

2009-04-15 06:17:00

- Adjusted EPS Growth of 15.9 Percent (GAAP EPS Growth of 53.3 Percent) - - Confirms Double-Digit EPS Guidance Range for 2009 - - Increased 2009 Dividend by 11 Percent - ABBOTT PARK, Ill., April 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2009. Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, and $0.03 above the mid-point of Abbott's previous first-quarter...

2009-01-26 07:00:00

Humira Will Retain its Status as Decision Resources' Clinical Gold Standard for Crohn's Disease Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 26, /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists say that a therapy's effect on maintenance of clinical remission is the attribute that most influences their choice in prescribing a...

2009-01-21 06:32:00

ABBOTT PARK, Ill., Jan. 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2008. -- Diluted earnings per share, excluding specified items, were $1.06, reflecting 14.0 percent growth, in line with Abbott's previous forecast. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.98, up 27.3 percent. -- Worldwide sales increased 10.1 percent...

2008-12-02 07:00:00

Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biologic agents, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will drive the moderate to severe psoriasis drug market to more than double to nearly $5 billion over the next decade....

2008-12-01 07:00:00

Increased Uptake of Current Agents and Emergence of New Therapies Will Drive Robust Annual Market Growth, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Abbott/Eisai's Humira is poised to overtake Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade as the Crohn's disease market leader by 2012. Humira will retain its...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related